cloprimed 5mg/ml (10mg/2ml) solution for injection (i.m./i.v.)
euro-med labs phils inc - metoclopramide (as hydrochloride) - solution for injection (i.m./i.v.) - 5mg/ml (10mg/2ml)
unbranded each ml contains 9 mg sodium chloride solution
euro-med labs phils inc - sodium chloride - solution - each ml contains 9 mg sodium chloride
unbranded none
euro-med labs phils inc - sterile water for injection - none
unbranded 50mg/ml solution for injection (im/iv)
euro-med labs phils inc - tramadol hydrochloride - solution for injection (im/iv) - 50mg/ml
blincyto
amgen europe b.v. - blinatumomab - precursor cell lymphoblastic leukemia-lymphoma - antineoplastic agents - blincyto is indicated as monotherapy for the treatment of adults with cd19 positive relapsed or refractory b precursor acute lymphoblastic leukaemia (all). patients with philadelphia chromosome positive b-precursor all should have failed treatment with at least 2 tyrosine kinase inhibitors (tkis) and have no alternative treatment options. blincyto is indicated as monotherapy for the treatment of adults with philadelphia chromosome negative cd19 positive b-precursor all in first or second complete remission with minimal residual disease (mrd) greater than or equal to 0.1%. blincyto is indicated as monotherapy for the treatment of paediatric patients aged 1 year or older with philadelphia chromosome negative cd19 positive b precursor all which is refractory or in relapse after receiving at least two prior therapies or in relapse after receiving prior allogeneic haematopoietic stem cell transplantation. blincyto is indicated as monotherapy for the treatment of paediatric patients aged 1 year or older with high-risk first relapsed philadelphia chromosome negative cd19 positive b-precursor all as part of the consolidation therapy (see section 4.2).,
4% dextrose in 0.18% sodium chloride -dr-xy24954 4g + 180mg / 100ml solution for intravenous infusion
euro-med laboratories phils inc - 4% dextrose in 0.18% sodium chloride - solution for intravenous infusion - 4g + 180mg / 100ml
extruss 8mg tablet
euro-med laboratories phils inc - bromhexine hydrochloride - tablet - 8mg
bupivacaine hydrochloride 5mg/ml (0.5%) solution for injection
euro-med laboratories phils inc - bupivacaine hydrochloride - solution for injection - 5mg/ml (0.5%)
eurocaine 10mg / ml (1%) solution for injection
euro-med laboratories phils inc - lidocaine hydrochloride (as monohydrate) - solution for injection - 10mg / ml (1%)
thalidomide lipomed
lipomed gmbh - thalidomide - multiple myeloma - immunosuppressants - thalidomide lipomed in combination with melphalan and prednisone is indicated as first line treatment of patients with untreated multiple myeloma, aged ≥ 65 years or ineligible for high dose chemotherapy.thalidomide lipomed is prescribed and dispensed in accordance with the thalidomide lipomed pregnancy prevention programme (see section 4.4).